ABL1 and intrahepatic cholangiocarcinoma: In addition to previously included PDGFRA, PDGFRB, FGFR1, and JAK2 fusions, FLT3 fusions and ETV6::ABL1 are now added to this category in both WHO-HAEM5 and ICC [39–41].